绿叶制药(02186.HK)曾飙八成至逾廿个月高 拟溢价引入高瓴资本为第二大股东
绿叶制药(02186.HK)拟溢价引入高瓴资本为第二大股东,消息刺激该股今早曾飙80%至7元创逾廿个月高,现造5.75元,急涨48%,一向薄弱成交激增至4.03亿股,为近几年罕见,涉资22.8亿元。
绿叶公布,公司拟以每股4.28元(较上周五收市价溢价10%)向Hillhouse NEV配售2.92亿股份新股。另外,公司控股股东Lu Ye Investment亦会以同价向Hillhouse出售2.6亿股持股。完成後,Hillhouse将持有公司现有已发股本15.6%,成为第二大股东。高瓴资本管理担任Hillhouse NEV的独家投资经理。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.